PUVA-induced acrobullous dermatosis

PUVA-induced acrobullous dermatosis is a rare skin condition that occurs as a side effect of PUVA therapy, a treatment involving the combination of psoralen (a drug) and ultraviolet A (UVA) light. This condition is characterized by the formation of blisters and erosions on the skin, particularly affecting the acral areas (hands and feet). PUVA therapy is commonly used to treat various dermatological disorders, including psoriasis, eczema, and vitiligo, by utilizing the photosensitizing properties of psoralen to enhance the skin's sensitivity to UVA light, thereby inhibiting abnormal cell growth and inflammation.

Symptoms and Diagnosis

The primary symptoms of PUVA-induced acrobullous dermatosis include the sudden appearance of blisters and erosions on the skin, especially on the palms, soles, and occasionally on the sides of the fingers and toes. These lesions can be painful and may lead to secondary infections if not properly managed. Diagnosis of this condition is primarily clinical, based on the patient's history of PUVA therapy and the presence of characteristic lesions. In some cases, a biopsy may be performed to rule out other blistering diseases and to confirm the diagnosis.

Treatment and Management

Treatment of PUVA-induced acrobullous dermatosis focuses on symptom management and prevention of further lesions. This may involve discontinuing PUVA therapy, depending on the severity of the condition and the underlying disorder being treated. Topical and systemic corticosteroids are often prescribed to reduce inflammation and pain. In addition, wound care measures, including the use of antiseptic dressings, are important to prevent secondary infections. Patients are also advised to avoid trauma or friction to affected areas to minimize the risk of new blisters forming.

Prevention

Preventive measures for PUVA-induced acrobullous dermatosis include careful monitoring of PUVA therapy doses and schedules to minimize the risk of overexposure to UVA light. Patients undergoing PUVA therapy should be educated about the potential side effects, including the risk of developing acrobullous dermatosis, and advised to report any unusual skin changes promptly.

Conclusion

PUVA-induced acrobullous dermatosis is a rare but significant complication of PUVA therapy. Awareness of this condition among healthcare providers and patients is crucial for early diagnosis and management. With appropriate treatment and preventive measures, patients can manage the symptoms of this condition and continue their PUVA therapy for the underlying dermatological disorder, if necessary.